Comparison of Amoxicillin/Clavulanic Acid High Dose with Cefdinir in the Treatment of Acute Otitis Media View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2012-11

AUTHORS

Janet R. Casey, Stan L. Block, Jim Hedrick, Anthony Almudevar, Michael E. Pichichero

ABSTRACT

BACKGROUND: 10 days of amoxicillin/clavulanic acid high dose and 5 days of cefdinir have been the preferred first- or second-line antibiotics for treatment of children with acute otitis media (AOM) since 2004, as recommended by the American Academy of Pediatrics in the USA, but no head-to-head comparison study has been done. OBJECTIVE: The purpose of the study was to compare the clinical efficacy of amoxicillin/clavulanic acid high-dose therapy for 10 days with cefdinir therapy for 5 days for AOM at recommended doses. METHODS: This was an investigator-blind trial in young children 6-24 months old with no history of recurrent AOM who were randomly assigned to amoxicillin/clavulanic acid (80 mg/kg/day amoxicillin) or cefdinir (14 mg/kg/day), both in two divided doses. The diagnosis of AOM was based on specific clinical criteria by validated otoscopists at two AOM research centres. The outcome measure for clinical cure was resolution of all symptoms and signs of AOM except for persistence of middle-ear effusion at test-of-cure (TOC) 11-14 days after initiation of antibiotic treatment. Clinical failure was defined as persistence of symptoms and signs of AOM and the need for additional antibiotic therapy. Subjects lost to follow up or who had not taken at least 80% of the prescribed medication were classified as having an indeterminate response. Compliance was monitored using Medical Electronic Monitoring System (MEMS) caps and antibiotic bottle volume measurement at the TOC visit. A logistic regression model was used to estimate the association of age with cure rate. Full interactions in terms of age with treatment were included to estimate any age gradient differential. RESULTS: A total of 330 children (average age 13.1 months) with AOM were studied. At TOC, 256 children had clinical cure, 69 had clinical failure, and 5 were lost to follow-up. High-dose amoxicillin/clavulanic acid-treated children had a better cure rate (86.5%) than cefdinir-treated patients (71.0%; p = 0.001). Cefdinir was correlated with less frequent cure outcomes as children increased in age between 6 and 24 months. The odds ratios for clinical cure per increasing month of age estimated from a logistic regression model for amoxicillin/clavulanic acid high dose and cefdinir treatment groups was 0.992 (95% CI 0.932, 1.056), p > 0.05 and 0.932 (95% CI 0.881, 0.986), p = 0.01. The differences in the odds ratios are significant at p < 0.002, indicating a stable clinical cure rate across the ages of children studied for amoxicillin/clavulanic acid and decreasing clinical cure rates as children increased in age for cefdinir. CONCLUSION: In children with bona fide AOM for whom clinical outcomes are assessed by validated otoscopists, 10 days of high-dose amoxicillin/clavulanic acid is significantly more effective than 5 days of cefdinir as therapy for AOM. Because of the identified age effect (correlated to child weight), higher doses of cefdinir may have led to a different conclusion; 10 days of cefdinir may also have led to a different conclusion. More... »

PAGES

1991-1997

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/11590320-000000000-00000

DOI

http://dx.doi.org/10.2165/11590320-000000000-00000

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1015284462

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23039319


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Acute Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Amoxicillin-Potassium Clavulanate Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Bacterial Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cephalosporins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Otitis Media", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Single-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Legacy Pediatrics, Rochester, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Casey", 
        "givenName": "Janet R.", 
        "id": "sg:person.01233644235.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01233644235.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Kentucky HealthCare", 
          "id": "https://www.grid.ac/institutes/grid.413001.7", 
          "name": [
            "Kentucky Pediatric Research, Bardstown, KY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Block", 
        "givenName": "Stan L.", 
        "id": "sg:person.07363123177.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07363123177.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Kentucky HealthCare", 
          "id": "https://www.grid.ac/institutes/grid.413001.7", 
          "name": [
            "Kentucky Pediatric Research, Bardstown, KY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hedrick", 
        "givenName": "Jim", 
        "id": "sg:person.0771335350.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0771335350.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Rochester", 
          "id": "https://www.grid.ac/institutes/grid.16416.34", 
          "name": [
            "Department of Biostatistics & Computational Biology, University of Rochester, Rochester, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Almudevar", 
        "givenName": "Anthony", 
        "id": "sg:person.01012507576.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012507576.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Rochester General Hospital", 
          "id": "https://www.grid.ac/institutes/grid.416016.4", 
          "name": [
            "Legacy Pediatrics, Rochester, NY, USA", 
            "Rochester General Hospital Research Institute, Center for Infectious Diseases and Immunology, 1425 Portland Avenue, 14621, Rochester, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pichichero", 
        "givenName": "Michael E.", 
        "id": "sg:person.0630132214.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630132214.91"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1097/01.inf.0000136868.91756.80", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004098265"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.inf.0000136868.91756.80", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004098265"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.inf.0000136868.91756.80", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004098265"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/inf.0b013e3181c1bc48", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006630581"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/inf.0b013e3181c1bc48", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006630581"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/inf.0b013e3181c1bc48", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006630581"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00006454-200012001-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011555926"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00006454-200012001-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011555926"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jac/dkg321", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012995876"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0022-3476(05)80601-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013381122"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.inf.0000137574.28711.c4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017165187"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.inf.0000137574.28711.c4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017165187"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.inf.0000137574.28711.c4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017165187"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.inf.0000136871.51792.19", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018566321"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.inf.0000136871.51792.19", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018566321"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/0009922811398391", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027053495"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/0009922811398391", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027053495"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.inf.0000202138.12950.3c", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040970258"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.inf.0000202138.12950.3c", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040970258"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.inf.0000202138.12950.3c", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040970258"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00148581-200406060-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052446618", 
          "https://doi.org/10.2165/00148581-200406060-00006"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00148581-200406060-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052446618", 
          "https://doi.org/10.2165/00148581-200406060-00006"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1542/peds.113.5.1451", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052969908"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-11", 
    "datePublishedReg": "2012-11-01", 
    "description": "BACKGROUND: 10 days of amoxicillin/clavulanic acid high dose and 5 days of cefdinir have been the preferred first- or second-line antibiotics for treatment of children with acute otitis media (AOM) since 2004, as recommended by the American Academy of Pediatrics in the USA, but no head-to-head comparison study has been done.\nOBJECTIVE: The purpose of the study was to compare the clinical efficacy of amoxicillin/clavulanic acid high-dose therapy for 10 days with cefdinir therapy for 5 days for AOM at recommended doses.\nMETHODS: This was an investigator-blind trial in young children 6-24 months old with no history of recurrent AOM who were randomly assigned to amoxicillin/clavulanic acid (80\u2009mg/kg/day amoxicillin) or cefdinir (14\u2009mg/kg/day), both in two divided doses. The diagnosis of AOM was based on specific clinical criteria by validated otoscopists at two AOM research centres. The outcome measure for clinical cure was resolution of all symptoms and signs of AOM except for persistence of middle-ear effusion at test-of-cure (TOC) 11-14 days after initiation of antibiotic treatment. Clinical failure was defined as persistence of symptoms and signs of AOM and the need for additional antibiotic therapy. Subjects lost to follow up or who had not taken at least 80% of the prescribed medication were classified as having an indeterminate response. Compliance was monitored using Medical Electronic Monitoring System (MEMS) caps and antibiotic bottle volume measurement at the TOC visit. A logistic regression model was used to estimate the association of age with cure rate. Full interactions in terms of age with treatment were included to estimate any age gradient differential.\nRESULTS: A total of 330 children (average age 13.1 months) with AOM were studied. At TOC, 256 children had clinical cure, 69 had clinical failure, and 5 were lost to follow-up. High-dose amoxicillin/clavulanic acid-treated children had a better cure rate (86.5%) than cefdinir-treated patients (71.0%; p\u2009=\u20090.001). Cefdinir was correlated with less frequent cure outcomes as children increased in age between 6 and 24 months. The odds ratios for clinical cure per increasing month of age estimated from a logistic regression model for amoxicillin/clavulanic acid high dose and cefdinir treatment groups was 0.992 (95% CI 0.932, 1.056), p\u2009>\u20090.05 and 0.932 (95% CI 0.881, 0.986), p\u2009=\u20090.01. The differences in the odds ratios are significant at p\u2009<\u20090.002, indicating a stable clinical cure rate across the ages of children studied for amoxicillin/clavulanic acid and decreasing clinical cure rates as children increased in age for cefdinir.\nCONCLUSION: In children with bona fide AOM for whom clinical outcomes are assessed by validated otoscopists, 10 days of high-dose amoxicillin/clavulanic acid is significantly more effective than 5 days of cefdinir as therapy for AOM. Because of the identified age effect (correlated to child weight), higher doses of cefdinir may have led to a different conclusion; 10 days of cefdinir may also have led to a different conclusion.", 
    "genre": "research_article", 
    "id": "sg:pub.10.2165/11590320-000000000-00000", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2489055", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1084788", 
        "issn": [
          "0012-6667", 
          "1179-1950"
        ], 
        "name": "Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "15", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "72"
      }
    ], 
    "name": "Comparison of Amoxicillin/Clavulanic Acid High Dose with Cefdinir in the Treatment of Acute Otitis Media", 
    "pagination": "1991-1997", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "48d2b442c1ff9c863baa2caf58e299ebf4028396588ec5bcc18e7cd581bf7c7f"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23039319"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7600076"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/11590320-000000000-00000"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1015284462"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/11590320-000000000-00000", 
      "https://app.dimensions.ai/details/publication/pub.1015284462"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T14:59", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8663_00000504.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.2165%2F11590320-000000000-00000"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/11590320-000000000-00000'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/11590320-000000000-00000'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/11590320-000000000-00000'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/11590320-000000000-00000'


 

This table displays all metadata directly associated to this object as RDF triples.

190 TRIPLES      21 PREDICATES      52 URIs      33 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/11590320-000000000-00000 schema:about N01300500bc734136ab4d4529658c1996
2 N29f69b2cf72e41c7930f59d7cff2e3ff
3 N499801f27c654059aeedfc75d6cb76d5
4 N70bdfe5fe861480bb4559925c36beb33
5 N82a69db0a31a4b9397dc8c3b51c035a3
6 Nac12fb4b903e406faa68a3715295b091
7 Nadc688b541a1433ab557d7014a6e04da
8 Nbbc504356afd4b498631ad622d6cd538
9 Nc51a742f692e47319926674959357ed0
10 Ndd52c11de20e4315a70adee3ba21fa04
11 Ne5c7f5cc8ad34a0d82b8212cdc78dc21
12 Nf19976557eaa4fcd9483d232602f7e72
13 anzsrc-for:11
14 anzsrc-for:1103
15 schema:author Nc1ca59bd9d8f4b928fd33a0def5c3af6
16 schema:citation sg:pub.10.2165/00148581-200406060-00006
17 https://doi.org/10.1016/s0022-3476(05)80601-8
18 https://doi.org/10.1093/jac/dkg321
19 https://doi.org/10.1097/00006454-200012001-00005
20 https://doi.org/10.1097/01.inf.0000136868.91756.80
21 https://doi.org/10.1097/01.inf.0000136871.51792.19
22 https://doi.org/10.1097/01.inf.0000137574.28711.c4
23 https://doi.org/10.1097/01.inf.0000202138.12950.3c
24 https://doi.org/10.1097/inf.0b013e3181c1bc48
25 https://doi.org/10.1177/0009922811398391
26 https://doi.org/10.1542/peds.113.5.1451
27 schema:datePublished 2012-11
28 schema:datePublishedReg 2012-11-01
29 schema:description BACKGROUND: 10 days of amoxicillin/clavulanic acid high dose and 5 days of cefdinir have been the preferred first- or second-line antibiotics for treatment of children with acute otitis media (AOM) since 2004, as recommended by the American Academy of Pediatrics in the USA, but no head-to-head comparison study has been done. OBJECTIVE: The purpose of the study was to compare the clinical efficacy of amoxicillin/clavulanic acid high-dose therapy for 10 days with cefdinir therapy for 5 days for AOM at recommended doses. METHODS: This was an investigator-blind trial in young children 6-24 months old with no history of recurrent AOM who were randomly assigned to amoxicillin/clavulanic acid (80 mg/kg/day amoxicillin) or cefdinir (14 mg/kg/day), both in two divided doses. The diagnosis of AOM was based on specific clinical criteria by validated otoscopists at two AOM research centres. The outcome measure for clinical cure was resolution of all symptoms and signs of AOM except for persistence of middle-ear effusion at test-of-cure (TOC) 11-14 days after initiation of antibiotic treatment. Clinical failure was defined as persistence of symptoms and signs of AOM and the need for additional antibiotic therapy. Subjects lost to follow up or who had not taken at least 80% of the prescribed medication were classified as having an indeterminate response. Compliance was monitored using Medical Electronic Monitoring System (MEMS) caps and antibiotic bottle volume measurement at the TOC visit. A logistic regression model was used to estimate the association of age with cure rate. Full interactions in terms of age with treatment were included to estimate any age gradient differential. RESULTS: A total of 330 children (average age 13.1 months) with AOM were studied. At TOC, 256 children had clinical cure, 69 had clinical failure, and 5 were lost to follow-up. High-dose amoxicillin/clavulanic acid-treated children had a better cure rate (86.5%) than cefdinir-treated patients (71.0%; p = 0.001). Cefdinir was correlated with less frequent cure outcomes as children increased in age between 6 and 24 months. The odds ratios for clinical cure per increasing month of age estimated from a logistic regression model for amoxicillin/clavulanic acid high dose and cefdinir treatment groups was 0.992 (95% CI 0.932, 1.056), p > 0.05 and 0.932 (95% CI 0.881, 0.986), p = 0.01. The differences in the odds ratios are significant at p < 0.002, indicating a stable clinical cure rate across the ages of children studied for amoxicillin/clavulanic acid and decreasing clinical cure rates as children increased in age for cefdinir. CONCLUSION: In children with bona fide AOM for whom clinical outcomes are assessed by validated otoscopists, 10 days of high-dose amoxicillin/clavulanic acid is significantly more effective than 5 days of cefdinir as therapy for AOM. Because of the identified age effect (correlated to child weight), higher doses of cefdinir may have led to a different conclusion; 10 days of cefdinir may also have led to a different conclusion.
30 schema:genre research_article
31 schema:inLanguage en
32 schema:isAccessibleForFree true
33 schema:isPartOf N0c245322b1c04c11a017bd98d6c0d0a0
34 N91d9d4983109499aa2b90f05470accc8
35 sg:journal.1084788
36 schema:name Comparison of Amoxicillin/Clavulanic Acid High Dose with Cefdinir in the Treatment of Acute Otitis Media
37 schema:pagination 1991-1997
38 schema:productId N10c71acb213a47948e01b87c0a0662dc
39 N578fe912a44d4830b67a94e3c429b35b
40 N8ff75ffe72cd482bab4303a95f8766ea
41 Nb07d1c43492f49ecbf9ae8bfb2110ee7
42 Nfb22e31bbb19462f846a1f86a0c5b24b
43 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015284462
44 https://doi.org/10.2165/11590320-000000000-00000
45 schema:sdDatePublished 2019-04-10T14:59
46 schema:sdLicense https://scigraph.springernature.com/explorer/license/
47 schema:sdPublisher Nfe2db74a7b984e2fbfd48f343edb61a8
48 schema:url http://link.springer.com/10.2165%2F11590320-000000000-00000
49 sgo:license sg:explorer/license/
50 sgo:sdDataset articles
51 rdf:type schema:ScholarlyArticle
52 N01300500bc734136ab4d4529658c1996 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
53 schema:name Follow-Up Studies
54 rdf:type schema:DefinedTerm
55 N0c245322b1c04c11a017bd98d6c0d0a0 schema:volumeNumber 72
56 rdf:type schema:PublicationVolume
57 N10c71acb213a47948e01b87c0a0662dc schema:name nlm_unique_id
58 schema:value 7600076
59 rdf:type schema:PropertyValue
60 N1438b6a055f94492ab086254417269ab rdf:first sg:person.0771335350.41
61 rdf:rest N7d40030b83a8484ba556889701b8c09a
62 N251e631b680f4810ba3fcfc37f0cb92e rdf:first sg:person.0630132214.91
63 rdf:rest rdf:nil
64 N29f69b2cf72e41c7930f59d7cff2e3ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
65 schema:name Treatment Outcome
66 rdf:type schema:DefinedTerm
67 N499801f27c654059aeedfc75d6cb76d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Infant
69 rdf:type schema:DefinedTerm
70 N4eef68f0c503409782b60b635506848e rdf:first sg:person.07363123177.77
71 rdf:rest N1438b6a055f94492ab086254417269ab
72 N578fe912a44d4830b67a94e3c429b35b schema:name dimensions_id
73 schema:value pub.1015284462
74 rdf:type schema:PropertyValue
75 N6af2c4f8ecb44197a8d5fbfffcba6f94 schema:name Legacy Pediatrics, Rochester, NY, USA
76 rdf:type schema:Organization
77 N70bdfe5fe861480bb4559925c36beb33 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Cephalosporins
79 rdf:type schema:DefinedTerm
80 N7d40030b83a8484ba556889701b8c09a rdf:first sg:person.01012507576.14
81 rdf:rest N251e631b680f4810ba3fcfc37f0cb92e
82 N82a69db0a31a4b9397dc8c3b51c035a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Prospective Studies
84 rdf:type schema:DefinedTerm
85 N8ff75ffe72cd482bab4303a95f8766ea schema:name readcube_id
86 schema:value 48d2b442c1ff9c863baa2caf58e299ebf4028396588ec5bcc18e7cd581bf7c7f
87 rdf:type schema:PropertyValue
88 N91d9d4983109499aa2b90f05470accc8 schema:issueNumber 15
89 rdf:type schema:PublicationIssue
90 Nac12fb4b903e406faa68a3715295b091 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Otitis Media
92 rdf:type schema:DefinedTerm
93 Nadc688b541a1433ab557d7014a6e04da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Drug Administration Schedule
95 rdf:type schema:DefinedTerm
96 Nb07d1c43492f49ecbf9ae8bfb2110ee7 schema:name doi
97 schema:value 10.2165/11590320-000000000-00000
98 rdf:type schema:PropertyValue
99 Nbbc504356afd4b498631ad622d6cd538 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Humans
101 rdf:type schema:DefinedTerm
102 Nc1ca59bd9d8f4b928fd33a0def5c3af6 rdf:first sg:person.01233644235.90
103 rdf:rest N4eef68f0c503409782b60b635506848e
104 Nc51a742f692e47319926674959357ed0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Acute Disease
106 rdf:type schema:DefinedTerm
107 Ndd52c11de20e4315a70adee3ba21fa04 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Anti-Bacterial Agents
109 rdf:type schema:DefinedTerm
110 Ne5c7f5cc8ad34a0d82b8212cdc78dc21 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Single-Blind Method
112 rdf:type schema:DefinedTerm
113 Nf19976557eaa4fcd9483d232602f7e72 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Amoxicillin-Potassium Clavulanate Combination
115 rdf:type schema:DefinedTerm
116 Nfb22e31bbb19462f846a1f86a0c5b24b schema:name pubmed_id
117 schema:value 23039319
118 rdf:type schema:PropertyValue
119 Nfe2db74a7b984e2fbfd48f343edb61a8 schema:name Springer Nature - SN SciGraph project
120 rdf:type schema:Organization
121 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
122 schema:name Medical and Health Sciences
123 rdf:type schema:DefinedTerm
124 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
125 schema:name Clinical Sciences
126 rdf:type schema:DefinedTerm
127 sg:grant.2489055 http://pending.schema.org/fundedItem sg:pub.10.2165/11590320-000000000-00000
128 rdf:type schema:MonetaryGrant
129 sg:journal.1084788 schema:issn 0012-6667
130 1179-1950
131 schema:name Drugs
132 rdf:type schema:Periodical
133 sg:person.01012507576.14 schema:affiliation https://www.grid.ac/institutes/grid.16416.34
134 schema:familyName Almudevar
135 schema:givenName Anthony
136 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012507576.14
137 rdf:type schema:Person
138 sg:person.01233644235.90 schema:affiliation N6af2c4f8ecb44197a8d5fbfffcba6f94
139 schema:familyName Casey
140 schema:givenName Janet R.
141 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01233644235.90
142 rdf:type schema:Person
143 sg:person.0630132214.91 schema:affiliation https://www.grid.ac/institutes/grid.416016.4
144 schema:familyName Pichichero
145 schema:givenName Michael E.
146 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630132214.91
147 rdf:type schema:Person
148 sg:person.07363123177.77 schema:affiliation https://www.grid.ac/institutes/grid.413001.7
149 schema:familyName Block
150 schema:givenName Stan L.
151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07363123177.77
152 rdf:type schema:Person
153 sg:person.0771335350.41 schema:affiliation https://www.grid.ac/institutes/grid.413001.7
154 schema:familyName Hedrick
155 schema:givenName Jim
156 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0771335350.41
157 rdf:type schema:Person
158 sg:pub.10.2165/00148581-200406060-00006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052446618
159 https://doi.org/10.2165/00148581-200406060-00006
160 rdf:type schema:CreativeWork
161 https://doi.org/10.1016/s0022-3476(05)80601-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013381122
162 rdf:type schema:CreativeWork
163 https://doi.org/10.1093/jac/dkg321 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012995876
164 rdf:type schema:CreativeWork
165 https://doi.org/10.1097/00006454-200012001-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011555926
166 rdf:type schema:CreativeWork
167 https://doi.org/10.1097/01.inf.0000136868.91756.80 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004098265
168 rdf:type schema:CreativeWork
169 https://doi.org/10.1097/01.inf.0000136871.51792.19 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018566321
170 rdf:type schema:CreativeWork
171 https://doi.org/10.1097/01.inf.0000137574.28711.c4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017165187
172 rdf:type schema:CreativeWork
173 https://doi.org/10.1097/01.inf.0000202138.12950.3c schema:sameAs https://app.dimensions.ai/details/publication/pub.1040970258
174 rdf:type schema:CreativeWork
175 https://doi.org/10.1097/inf.0b013e3181c1bc48 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006630581
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1177/0009922811398391 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027053495
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1542/peds.113.5.1451 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052969908
180 rdf:type schema:CreativeWork
181 https://www.grid.ac/institutes/grid.16416.34 schema:alternateName University of Rochester
182 schema:name Department of Biostatistics & Computational Biology, University of Rochester, Rochester, NY, USA
183 rdf:type schema:Organization
184 https://www.grid.ac/institutes/grid.413001.7 schema:alternateName University of Kentucky HealthCare
185 schema:name Kentucky Pediatric Research, Bardstown, KY, USA
186 rdf:type schema:Organization
187 https://www.grid.ac/institutes/grid.416016.4 schema:alternateName Rochester General Hospital
188 schema:name Legacy Pediatrics, Rochester, NY, USA
189 Rochester General Hospital Research Institute, Center for Infectious Diseases and Immunology, 1425 Portland Avenue, 14621, Rochester, NY, USA
190 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...